Related by context. All words. (Click for frequent words.) 68 Phase Ia Ib 58 Phase 1b clinical trials 58 recurrent metastatic 58 Combination REOLYSIN R 57 Aplidin 57 REOLYSIN ® 57 phase Ib 57 randomized multicentre 57 TheraCIM h R3 57 pharmacokinetic PK study 57 Allovectin 7 57 EOquin TM 56 Phase Ib clinical 56 multicenter Phase II 56 ZACTIMA 56 UPLYSO 56 farletuzumab 56 Phase Ib II 56 paclitaxel poliglumex 55 OvaRex MAb 55 YONDELIS 55 recurrent malignant glioma 55 Bayer HealthCare Onyx Pharmaceuticals 55 VNP#M 55 Quinamed 55 Phase #b/#a clinical 55 demonstrated antitumor activity 55 ixabepilone 55 dose escalation clinical 55 MAGE A3 ASCI 55 biliary tract cancer 55 inhaled AAT 54 phase IIb III 54 Cloretazine ® 54 Opterone 54 BrachySil 54 preclinical efficacy 54 Onalta ™ 54 Phase 1b clinical 54 IIa trials 54 Novo TTF 54 dose escalation Phase 54 candidates Dyloject TM 54 bavituximab monotherapy trial 54 GLP toxicology studies 54 GeneICE 54 Amrubicin 54 NCIC CTG 53 Phase IIb III 53 OLYMPIA registry 53 BrachySil TM 53 fosbretabulin 53 OvaRex ® MAb 53 phase IIa 53 IIa clinical trial 53 LBH# 53 receptor tyrosine kinase inhibitor 53 Phase 1a clinical 53 PI3K/Akt pathway inhibitor 53 PEG IFN 53 BNC# 53 pharmacodynamic PD 53 IIa clinical trials 53 Panzem R NCD 53 Phase Ia 53 afamelanotide 53 trastuzumab DM1 T DM1 53 BRIM3 53 BRIM2 53 randomized Phase IIb 53 liposome formulation 52 liposomal doxorubicin 52 Urocidin 52 Orazol 52 PEGylated interferon 52 Benlysta belimumab 52 Phase IIIb clinical 52 Phase III randomized controlled 52 HuMax EGFr 52 DCVax ® Brain 52 eribulin mesylate 52 multicenter randomized controlled 52 Proellex TM 52 COMFORT II 52 MGN# 52 IIb clinical trial 52 NO# [002] 52 trastuzumab emtansine T DM1 52 OncoGel 52 gemcitabine carboplatin 52 Phase III psoriasis 52 ELACYT 52 Fodosine 52 thorough QT 52 CLORETAZINE TM VNP#M 52 IIa trial 52 oral rivaroxaban 52 bortezomib Velcade 52 fluoropyrimidine 52 acyclovir Lauriad R 52 LymphoStat B TM 52 multicenter phase 51 somatostatin receptor 51 Vectibix panitumumab 51 Phase Ib study 51 multicenter clinical 51 alvespimycin 51 rALLy trial 51 CRLX# 51 multicentre randomized 51 Zemplar Capsules 51 Randomized controlled 51 Phase IIIb 51 neratinib 51 TransMID 51 Trovax 51 multicenter prospective 51 Exherin TM 51 liposomal formulation 51 ReN# 51 ATL# [001] 51 Pivotal Phase III 51 Dacogen injection 51 Allovectin 7 ® 51 Reolysin 51 platinum refractory 51 hypoxia activated prodrug 51 oral deforolimus 51 antimitotic 51 trastuzumab DM1 51 androgen receptor antagonist 51 confirmatory Phase 51 generation purine nucleoside 51 perifosine KRX 51 Proxinium TM 51 BLA filing 51 Lucanix 51 PrevOnco 51 phase 2a 51 oral picoplatin 51 IIa Clinical Trial 51 PrevOnco ™ 51 Alocrest 51 inecalcitol 51 CLIRS 51 Panzem NCD 51 temozolomide TMZ 50 Tarceva TM 50 Motesanib 50 RE MODEL 50 phase IIa clinical 50 dose cohort 50 intravenous dosing 50 multicenter Phase 50 Phase III 50 docetaxel Taxotere ® 50 intratumoural 50 TMC# [002] 50 Exelixis compounds 50 Phase 1a 50 murine models 50 rALLy clinical trial 50 Phase IIA 50 APEX PD 50 anastrazole 50 Saforis 50 phase IIb 50 TASKi3 50 AKT inhibitor 50 BR.# 50 TQT 50 depsipeptide 50 epothilone KOS 50 trials RCTs 50 phase IIIb 50 Capesaris 50 LAB CGRP 50 tramiprosate Alzhemed TM 50 Dyloject TM 50 tolevamer 50 multicenter randomized placebo controlled 50 ToGA 50 Multikine ® 50 dose escalation trial 50 SUCCEED trial 50 randomized controlled multicenter 50 placebo controlled Phase 50 Trastuzumab DM1 50 prospective multicenter 50 Phase lll 50 Phase #b/#a trial 50 lorvotuzumab mertansine 50 initiated Phase Ib 50 ruxolitinib 50 relapsing remitting MS RRMS 50 PFO migraine 50 Phase 2b kidney transplant 50 MGd 50 Degarelix 50 NP2 Enkephalin 50 Randomised 50 pharmacokinetic PK 50 TASQ 50 Multiple Ascending Dose 50 irinotecan oxaliplatin 50 gemcitabine Gemzar ® 50 prospectively defined 50 PROVENGE ® 50 Phase 1b trial 50 evaluating mipomersen 50 BiTE R 50 Phase III pivotal 50 NSABP B 50 CHAMPION PCI 49 Curaxin CBLC# 49 Achieves Primary Endpoint 49 Phase Ib 49 Phase Ib IIa 49 phase IIb clinical 49 VESTASYNC 49 ANCHOR trial 49 Phase 2a clinical 49 SUTENT ® 49 Sorafenib HCC Assessment 49 tanespimycin 49 STRIDE PD 49 LUX Lung 49 RE SURGE 49 mg/m2 cohort 49 Valtropin 49 gemcitabine Gemzar 49 CLARITY study 49 REMUNE R 49 forodesine 49 tumorigenicity 49 OvaRex R 49 Archexin 49 oral ridaforolimus 49 Phase III multicenter 49 Aryplase 49 mitogen activated ERK kinase 49 Xelox 49 Telatinib 49 IMA# 49 PSMA ADC 49 including eniluracil ADH 49 novel VDA molecule 49 Ereska 49 refractory prostate cancer 49 PRESEPT study 49 BST CarGel R 49 randomized controlled Phase 49 dose dose escalation 49 Phase #b/#a 49 EOquin 49 Ophena 49 antibody MAb 49 ADAGIO study 49 vemurafenib 49 phase IIb trial 49 dirucotide MBP# 49 pivotal bioequivalence 49 IIa clinical 49 Cloretazine R 49 Onconase 49 EURIDIS 49 treatment naive genotype 49 confirmatory Phase III 49 Zybrestat 49 temsirolimus Torisel ® 49 TG# [001] 49 APPRAISE 49 Denufosol 49 radiation dosimetry 49 Phase IIB 49 Trofex 49 mertansine 49 rALLy 49 registrational 49 riociguat 49 pivotal Phase 49 randomized Phase III 49 labial herpes 49 OvaRex 49 EndoTAG 49 Successfully Completes Phase 49 IIIA NSCLC 49 registrational Phase 49 Ophena TM 49 Bezielle 49 stage IIIB 49 acute HAE attacks 48 microRNA profiling 48 vidofludimus 48 masked placebo controlled 48 multidose 48 randomized multicenter Phase III 48 targeted tyrosine kinase 48 EXPLORE Xa 48 non nucleoside 48 AE# vaccine 48 prospective randomized multicenter 48 HuMax CD#b 48 PANVAC VF 48 ritonavir boosted 48 evaluating Xcytrin 48 galiximab 48 Pharmacokinetic PK 48 Initiated Phase 48 randomized discontinuation trial 48 MKC# MT 48 CUSTOM III 48 Phase IIb clinical trials 48 e2 Collector 48 Phase IIb clinical 48 Bruton tyrosine kinase Btk 48 orally inhaled 48 DIABECELL R 48 Flutiform ™ 48 TMC# C# 48 Prostate AdenoCarcinoma Treatment 48 KRN# 48 evaluating Prochymal 48 Pivotal Trial 48 clinical trial 48 CytoFabTM 48 subcutaneous methylnaltrexone 48 Phase 1b 48 Zemiva ™ 48 budesonide foam 48 Apoptone 48 Phase 2a 48 Virulizin ® 48 haematological 48 Angiolix 48 randomized #:#:# 48 Neuvenge 48 Efficacy Trial 48 olanzapine LAI 48 tumor histology 48 Pralatrexate 48 ritonavir boosted protease inhibitor 48 Phase III Clinical Trial 48 huN# DM1 48 SEPET TM 48 tezampanel NGX# 48 adjuvant colon cancer 48 dosing cohort 48 biodistribution studies 48 Tesetaxel 48 Randomized Phase II 48 Raloxifene STAR 48 Phase II 48 oral methylnaltrexone 48 Raptiva ® 48 multicentre 48 ASA# 48 lintuzumab 48 DACH platinum 48 retaspimycin 48 drug NP2 Enkephalin 48 HCV SPRINT 48 Phase III Psoriasis 48 IMPACT DCM 48 satraplatin Phase 48 Pivotal Study 48 CRMD# 48 Alpharadin 48 bortezomib Velcade R 48 NADiA 48 phase Ib clinical 48 TEMSO 48 NOD SCID mice 48 PRIMO CABG 48 SYMMETRY trial 47 radioprotection 47 Azedra 47 topoisomerase II inhibitor 47 oral COTI 47 Tykerb lapatinib 47 Apaziquone 47 nonrandomized 47 Solorel 47 Cloretazine 47 tumor necrosis 47 PERSEUS 47 scintigraphic 47 AVADO 47 Phase Ib clinical trials 47 Trial Evaluating 47 LymphoStat B belimumab 47 randomized Phase 2b 47 CBLC# 47 docetaxel Taxotere R 47 MVax 47 Alzhemed TM 47 Commence Phase 47 pharmacokinetic parameters 47 ADVANCE PD 47 cilengitide 47 evaluating satraplatin plus 47 orally dosed 47 SAR# [004] 47 MS spasticity 47 ascending dose 47 pivotal Phase III 47 next generation URAT1 47 Phase 47 Tocosol 47 Phase Ib IIa clinical 47 huC# DM4 47 lorcaserin Phase 47 GAMMAGARD 47 Pivotal Clinical Trial 47 assessing T DM1 47 pramlintide metreleptin combination 47 Phase 2a trial 47 EchoCRT 47 HuMax CD4 47 SNT MC# 47 preclinical pharmacokinetic 47 MIST II 47 Phase IIIb study 47 confirmatory clinical 47 Genz # 47 Genasense oblimersen sodium Injection 47 DermaVir Patch 47 StemEx 47 PF # [002] 47 registrational trial 47 HCV RESPOND 2 47 pharmacokinetic studies 47 VIR# 47 cetrorelix pamoate 47 intratumoral 47 oral treprostinil 47 MKC# 47 florbetaben 47 evaluable patients 47 hepatitis B vaccine Heplisav 47 Canvaxin 47 Diamyd ® 47 initiate Phase IIa 47 placebo controlled clinical 47 ILLUMINATE 47 efficacy endpoint 47 Harry Palmin President 47 LibiGel Phase III 47 PDX pralatrexate 47 blinded randomized controlled 47 Initiate Phase 47 Phase III VISTA 47 Phase 2a preventative 47 Aplidin R 47 Darusentan 47 ENRICH trial 47 axitinib 47 RhuDex ® 47 GetGoal Phase III 47 DEEP AF 47 Allovectin 7 R 47 RELOVAIR ™ 47 Val HeFT 47 AQ4N 47 ARRY # 47 nab paclitaxel 47 DIABECELL ® 47 multicenter randomized Phase 47 randomized multicenter trial 47 SinuNase TM 47 randomized discontinuation 47 tumor xenograft models 47 IMC #B 47 multicenter dose escalation 47 Clinical Trial Results 47 TQT studies 47 DiabeCell 47 Nimotuzumab 46 omacetaxine mepesuccinate 46 GVAX R 46 randomized multicenter 46 Aflibercept 46 imetelstat GRN#L 46 CTA# 46 TLK# 46 dose escalation study 46 CAMMS# 46 CytoFab ™ 46 confirmatory pivotal 46 microdose 46 aclidinium bromide 46 TBC# 46 Company proprietary INACTINE 46 Vitaxin 46 OncoVEX GM CSF 46 recurrent glioma 46 neurologic progression 46 Annamycin 46 Insulin PH# 46 sunitinib malate 46 ORBIT II 46 SCENESSE ® 46 immatics 46 LB# [003] 46 ENESTnd 46 Phase 2b clinical trials 46 Phase IIa clinical 46 velafermin 46 ABSORB trial 46 phase IIb study 46 BIBW 46 placebo controlled randomized 46 Phase III clinical 46 CANCIDAS 46 cathepsin K inhibitor 46 pertuzumab 46 Fentanyl TAIFUN R 46 Plicera 46 Asentar 46 unique alkylating agent 46 Phase 2b study 46 Novolimus 46 AIR# [001] 46 RIO Lipids 46 DermaVir 46 GV# [001] 46 Cloretazine R VNP#M 46 Onglyza saxagliptin 46 RE LY 46 Subgroup analysis 46 dose escalation 46 Lovaxin C 46 Curaxin 46 ongoing Phase 1b 46 Phase 2b trial 46 dosage regimens 46 nanopharmaceutical 46 Alequel ™ 46 FlutiformTM 46 selective orally bioavailable 46 TPI ASM8 46 candidate Liposomal Grb 46 dosing cohorts 46 Pre RELAX AHF 46 TOLAMBA 46 aleglitazar 46 pharmacokinetic pharmacodynamic 46 novel histone deacetylase 46 VEGFR2 inhibitor 46 PROTECT AF 46 DASISION 46 vosaroxin 46 GALNS 46 mg administered orally 46 multicentre study 46 PREVENT IV 46 delipidation 46 glufosfamide 46 xenograft models 46 Phase III HEAT 46 INTELENCE 46 Amigal 46 Androxal TM 46 CLL SLL 46 Randomized Phase 46 Daclizumab 46 Phase IIa trials 46 blinded randomized placebo controlled 46 TG MV 46 paclitaxel Taxol ® 46 Placebo controlled 46 tosedostat 46 FM VP4 46 Syncria albiglutide 46 pharmacokinetic characteristics 46 Confirmatory Phase 46 iii GTx 46 peptide conjugated 46 EGS# 46 Ceflatonin R 46 ONCONASE R 46 vinca alkaloid 46 TIMP 1 46 romidepsin 46 motesanib 46 Phase IIa trial 46 ancrod 46 Advagraf 46 Hedgehog pathway inhibitor 46 Phase #/#a trial 46 Glufosfamide 46 volociximab 46 Sutent sunitinib 46 SELZENTRY 46 elacytarabine 46 olaparib 46 novel immunotherapeutic 46 MEND CABG II 46 FOLOTYN ® 46 evaluating bafetinib 46 Neo Bladder Augment 46 LibiGel testosterone gel 46 Phase III confirmatory 46 Phase 2b randomized 46 Hyphanox 46 Oglemilast 46 CARE HF 46 Augment Injectable 46 DEB# 46 TASKi2 46 OncoVex 46 metastatic castrate resistant 46 BENLYSTA ® 46 AMPAKINE CX# 46 seliciclib CYC# 46 oral prodrug 46 double blinded placebo 46 eliglustat tartrate 46 Pivotal Phase II 46 GSK# [001] 46 Completes Patient Enrollment 46 Phase IIb trials 46 ceftazidime 46 PROSTVAC TM 46 Lupuzor 46 ritonavir boosted danoprevir 46 CURE AF 46 preclinical xenograft models 46 AST ALT 45 VITAL Trial 45 FORTIS M trial 45 ZYBRESTAT fosbretabulin 45 Phase IIa Clinical Trial 45 HGS ETR1 45 BOLDER II 45 Phase III TRIST 45 LUMINATE 45 QT QTc 45 paclitaxel Taxol 45 Spiegelmer ® 45 Immunitor 45 ICA # 45 dosimetry 45 telomerase therapeutic 45 MEND CABG 45 Phase 2b 45 mCi 45 Advaxis Phase 45 blinatumomab 45 Atu# 45 Phase III Clinical Trials 45 Traficet EN 45 cytotoxicity assays 45 chemo immunotherapy 45 HER2 antibody 45 maximally tolerated dose 45 celgosivir 45 anti leukemic 45 pediatric glioma 45 immunostaining 45 resminostat 45 pharmacokinetics PK 45 efavirenz EFV 45 Dose Escalation Study 45 randomized Phase 45 ganetespib 45 multicenter Phase III 45 Phase IIb 45 MIRCERA 45 omiganan 45 CCR5 inhibitor 45 prospective randomized controlled 45 torezolid phosphate 45 IMC A# 45 candidate CRLX# 45 lenalidomide dexamethasone 45 ToleroMune 45 multicentre randomized controlled 45 relapsed refractory multiple myeloma 45 sodium thiosulfate STS 45 Lucanix R 45 blind multicenter 45 tolerability profiles 45 double blinded randomized 45 II Clinical Trial 45 placebo controlled Phase III 45 trastuzumab Herceptin ® 45 TELCYTA 45 Cannabinor 45 pharmacodynamic properties 45 ALSYMPCA 45 XL# SAR# 45 kinase inhibition 45 Medidur TM FA 45 Telintra 45 Ozarelix 45 NSABP C 45 WX UK1 45 treatment naïve genotype 45 controlled multicenter Phase 45 vivo potency 45 R roscovitine 45 DDP# 45 NSABP 45 ozarelix 45 doxorubicin docetaxel 45 telaprevir dosing 45 ascending doses 45 TSQ Quantum 45 GRNVAC1 45 combretastatin A4 phosphate CA4P 45 cannabinor 45 AP# [003] 45 Initiates Phase II 45 Phase III randomized 45 RECORD1 45 Elagolix 45 Elocalcitol 45 prospective multicenter randomized 45 enzastaurin 45 Dendreon Provenge 45 human secretin 45 APTIVUS 45 multicenter randomized clinical 45 peptide fragment 45 PRE SURGE 45 REALITY Trial 45 metformin XR 45 bortezomib Velcade ® 45 MyVax personalized immunotherapy 45 multicentre phase 45 EDEMA3 45 ularitide 45 eniluracil 45 immunofluorescence staining 45 crizotinib PF # 45 sequential dose escalation 45 Cloretazine VNP#M 45 SILENOR 45 PreCISe 45 PS# DARA 45 subgroup analyzes 45 viral kinetic 45 grade cervical dysplasia 45 CDK inhibitor 45 incyclinide 45 Rheos System 45 randomized clinical 45 Sapacitabine 45 KSP inhibitor 45 ZALBIN dosed 45 Atiprimod 45 QNEXA ® 45 initiate multicenter 45 4mg/kg 45 PSN# [002] 45 Anthim 45 Phase III Trial 45 MyVax 45 BETAS 45 MOTIVATE 45 RG# [001] 45 REVIVE Diabetes 45 HCV protease inhibitors 45 M Vax 45 PREOS R 45 ENDEAVOR III 45 blinded placebo controlled 45 urodynamic 45 dose pharmacokinetic 45 bispecific antibody 45 Phase 2b Study 45 ISEL 45 lead Aganocide compound 45 INSPIRE Trial Phase III 45 busulfan 45 TELINTRA R 45 SparVax TM 45 CTA# Injection 45 Mylotarg 45 Dose Ranging Study 45 ticagrelor Brilinta 45 BACcel 45 specified primary endpoint 44 VersaFilm 44 xenograft mouse 44 Feasibility Trial 44 TAFA# 44 MoxDuo ® 44 IMPACT IMmunotherapy 44 solithromycin 44 Phase 2b clinical 44 ADMIRE HF 44 Oral NKTR 44 Telcyta 44 GOUT 44 bardoxolone 44 tesmilifene 44 HEPLISAV TM 44 Phase III clinical trials 44 Enzastaurin 44 torezolid 44 mapatumumab 44 COSTAR II 44 Amoxicillin PULSYS Phase III 44 WHIMS 44 PHX# 44 randomized blinded 44 CanAg 44 hematopoietic cancers 44 Phase IIa clinical trials 44 ASCEND HF 44 Edwards SAPIEN valve 44 Commences Phase 44 fostamatinib 44 immune modulating 44 Phase #/#a 44 albiglutide 44 selective adenosine 44 tumor specific antigen 44 Phase 2b Clinical Trial 44 genotypic resistance 44 ZYBRESTAT TM 44 Investigational Device Exemption IDE 44 Vaxfectin TM 44 lenalidomide Revlimid R 44 AzaSite Plus 44 Lock Loop PLL 44 Peregrine bavituximab 44 DIABECELL 44 BEZ# 44 MedPulser ® 44 clinical trials 44 DiabeCell R 44 ganaxolone 44 Phase IIb trial 44 initiate Phase 2b 44 ASSERT trial 44 Phase 2a Trial 44 multiplex assay 44 Anturol TM 44 clinical trials Archexin 44 Varisolve 44 MEK inhibitor RDEA# 44 RE LY ® 44 gepirone ER 44 ESBA# 44 pharmacokinetic profiles 44 PDE4 inhibitor 44 Protease Inhibitor 44 JAK inhibitor 44 Ispinesib SB # 44 placebo controlled multicenter 44 boosted protease inhibitor 44 NEVO RES 44 Phase IIa proof 44 initiate Phase IIb 44 vaccine Stimuvax 44 includes TOLAMBA TM 44 CRD5 44 Investigational Device Exemption 44 ENGAGE AF TIMI 44 ACOSOG Z# 44 dose cohorts 44 relapsing multiple sclerosis 44 Abbott ARCHITECT 44 Phase IIb Trial 44 Pharmacokinetic Study 44 Pimavanserin 44 Serada 44 Xcellerated T Cells 44 TAXUS ATLAS 44 beta2 agonist 44 controlled multicenter 44 L BLP# 44 INCB# [002] 44 Tocosol Paclitaxel 44 cancer neuroendocrine tumor 44 Huaiyin Power Plant 44 Mipomersen 44 NVA# 44 BIIB# 44 fidaxomicin Phase 3 44 ProLindac 44 HGS# 44 intratumoral injection 44 Testosterone MDTS ® 44 immunotoxin 44 baminercept 44 #mg ATC 44 Tolerability Study 44 pegnivacogin 44 XP #L 44 Visipaque 44 methotrexate therapy 44 Metastatic Melanoma 44 non nucleoside HCV 44 ATTRACT 44 alpha fetoprotein AFP 44 oral taxane 44 Cetrorelix 44 lipopeptide 44 CEQ# 44 dose escalation phase 44 Omapro 44 Biopharmaceuticals AG 44 brentuximab vedotin SGN 44 Aclidinium 44 stated Michelle Berrey 44 pharmacodynamic endpoints 44 prognostic biomarker 44 pharmacodynamic effects 44 tumor subtypes 44 CVBT #H 44 #:# randomization 44 intravenous picoplatin 44 INCB# [001] 44 dependent kinase inhibitor 44 Multimeric 44 Initiates Clinical 44 Scopus Affiliation Identifier 44 Enobia 44 ChronVac C ® 44 DNA intercalator 44 Dynavax HBV vaccine 44 LCP AtorFen 44 naltrexone SR 44 LC#m# 44 OMP #M# 44 CURRENT OASIS 7 44 IND submission 44 tacrolimus ointment 44 HDACi 44 HCV replicon 44 potent antitumor activity 44 multicenter randomized 44 metabolite identification 44 isavuconazole 43 Liprostin 43 bioabsorbable stent 43 treat premature ejaculation 43 fidaxomicin Phase 43 prospective randomized 43 metastatic hormone refractory 43 AOD# [002] 43 Pivotal Trials 43 clinical pharmacology studies 43 IMGN# 43 TOCOSOL Paclitaxel 43 PEARL SC 43 Tyrima 43 ANAVEX #-# [001] 43 rindopepimut 43 RiVax 43 SPIRIT FIRST 43 unresectable stage 43 UVIDEM 43 obatoclax 43 ORMD 43 ALN VSP Phase 43 BLOOM DM 43 VALOR trial 43 EndoTAG TM -1 43 EPC# 43 NRTI resistance 43 adecatumumab MT# 43 Aurora kinase inhibitor 43 AIR CF2 43 gastric ovarian 43 PRTX 43 chemotherapeutic drug 43 RESTORE CLI trial 43 PD2i CA 43 ALK inhibitors 43 RSD# oral 43 RhuDex 43 subanalysis 43 palifosfamide Zymafos TM 43 DCCR 43 elotuzumab 43 #DF [001] 43 FORTIS M 43 AVN# Phase 43 M1 muscarinic 43 ART# 43 NEO3 43 SIMPADICO 43 rotary VAD 43 Twinrix 43 urocortin 2 43 Phase IIB clinical 43 Ofatumumab 43 XL# [003] 43 MEK inhibitors 43 XTEN 43 multicenter placebo controlled 43 lasofoxifene 43 TEC #OL 43 HPV genotyping